Qihan Biotech Received $20 Million In The Newest Round Of Financing

Qihan Biotech just received 20 million dollars in the newest round of financing, this round of financing was led by CMB International and Legend Star. The funds will be used to build a genetic modification platform, and promote the development of xenotransplantation.

Founded in 2017, Qihan Biotech is a biotechnology company that specializes in applying the latest gene-editing technology to xenotransplantation to address the global shortage of organ donors. The company was founded by the founder and chief scientist of eGenesis Dr. Luhan Yang and Harvard professor George Church.

Dr. Luhan Yang's team developed the first generation of piglets in 2017, which solved a safety problem of xenotransplantation and established the world's most advanced animal genetic modification platform. George Church is a professor of genetics at Harvard Medical School and the head of the Human Genome Project Organization (PGP). His team invented the human stem cell genome CRISPR editing technology and other synthetic biology techniques, including new methods for transplanting organs. Gene therapy for aging reversal, and genetic techniques for eliminating Lyme disease and malaria.

Millions of patients in China have advanced organ failure, and most patients lose their lives while waiting for new organs. Qihan Biotech is committed to using the most advanced genetic technologies and drugs to create organs that can be transplanted, giving patients the opportunity to survive.

CMB International is an investment banking firm that offers comprehensive professional services and financial advisory services. It provides mergers and acquisitions, initial public offering, equity underwriting, company restructuring, project financing, and business consulting services.

Legend Star Specializes in early-stage investments in technologies transforming traditional industries in China.